CleveMed Strengthens Its Intellectual Property with Positive Airway Pressure Technologies for At-Home Therapy Monitoring

“A main challenge of any home test is patient ease-of-use and data quality”

CleveMed, Cleveland, OH – Aug 16, 2017 – CleveMed, a leading provider of home sleep apnea monitoring solutions was issued another important patent (US Patent No. 9,730,632) entitled “Integrated sleep diagnostic and therapeutic system and method”. The patent covers communication between Positive Airway Pressure (PAP) therapy machines and home diagnostic monitors to generate an easy and detailed reporting of patient’s health during therapy for determining efficacy and titrating therapy. PAP is by far the most popular sleep apnea therapy with millions of new patients receiving treatment every year. The demand is driving the need for an easy and cost effective method to evaluate these patients over time without bringing them back into the sleep lab. “Our IP position is quite strong in this area; this is our fifth issued patent with a number of other patent applications pending”, said Dr. Brian Kolkowski, CleveMed Executive Vice President and patent attorney.

“A main challenge of any home test is patient ease-of-use and data quality. Our patents simplify sensor data acquisition by merging PAP data with home diagnostic monitors through many means including wireless communication. In addition to simplicity of operation, the merged data generates more comprehensive reports of patient’s response to treatment directly from the home, which can help physicians intervene in a manner that is faster and more cost-effective than current methods,” said Hani Kayyali, CleveMed CEO.

Obstructive sleep apnea (OSA), the most prevalent form of sleep apnea, is a repeated interruption of normal breathing during sleep due to a collapse of the upper airway. It is estimated to impact as many people as asthma and diabetes; yet, up to 80 percent of the population with the disease remain undiagnosed and untreated. Moreover, OSA leads to serious health and economic consequences. Numerous studies link OSA to major chronic diseases such as stroke, heart failure, diabetes, obesity, hypertension and increased odds of serious car crash injuries. Such co-existing conditions can alter patient’s ability to benefit from sleep apnea therapy, and therefore could necessitate the re-evaluation of treatment.

CleveMed is a fast growing company with a wide range of sleep testing equipment, services, and cloud based technologies that allow sleep disorders to be monitored in the home, including Sapphire PSG™, SleepScout™, SleepView®, SleepViewSM Web-portal, and SleepView Direct. CleveMed’s goal is to expand the reach of sleep medicine with technologies that speed diagnosis for providers, reduce healthcare costs for payers, and improve patients’ experiences in the home. For more information, please visit https://CleveMed.com (Follow us on twitter, youtube, LinkedIn, and facebook). SleepView is a registered trademark and a service mark, and Sapphire PSG and SleepScout are trademarks of Cleveland Medical Devices Inc. of Cleveland, OH.

August 16th, 2017|